MIAMI, March 6, 2008 (PRIME NEWSWIRE) -- Galea Life Sciences, Inc. (Pink Sheets:GLSN), whose BioSource Therapeutics, Inc. (BST) subsidiary manufactures and markets Nutraplete(tm) Therapeutic Drink Mix, the first dietary supplement produced specifically for people living with HIV/AIDS, has completed a $275,000 convertible debenture financing with Trafalgar Capital Specialized Investment Fund, Luxembourg.
